Driving CAR T cell translation forward

Sci Transl Med. 2019 Feb 27;11(481):eaaw2127. doi: 10.1126/scitranslmed.aaw2127.

Authors

Liora Schultz¹, Crystal Mackall^{2

3

4}

Affiliations

¹ Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
² Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA. cmackall@stanford.edu.
³ Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
⁴ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.

PMID: 30814337
DOI: 10.1126/scitranslmed.aaw2127

Abstract

Successes in CAR T cell translation have propelled their commercial launch, but expanding the impact of cancer immunotherapies remains challenging.

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Publication types

Review

MeSH terms

Animals
Antigens, CD19 / metabolism
Cell Proliferation
Humans
Immunotherapy, Adoptive*
Recurrence
T-Lymphocytes / immunology
Translational Research, Biomedical*

Substances

Antigens, CD19